Injectafer (Ferric Carboxymaltose)

Ferric carboxymaltose delivers a stable iron complex that is taken up by reticuloendothelial cells after infusion. The iron is then released, bound to transferrin, and becomes available for incorporation into hemoglobin and other iron‑dependent proteins, effectively correcting iron deficiency.

The prescribed dose of Injectafer is individualized by the treating physician based on the patient’s iron deficit, body weight, and clinical condition. The healthcare provider determines the total iron requirement and the infusion schedule, ensuring safe and effective therapy.

Injectafer is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy or lactation when the potential benefit justifies the potential risk, and the decision should be made by the prescribing clinician.

To order Injectafer, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details—including cold‑chain handling if needed—and the necessary import documentation.

Injectafer (ferric carboxymaltose) offers a high‑dose, single‑visit infusion option, allowing up to 1000 mg of iron to be administered in a short period. Compared with older iron sucrose formulations, it requires fewer infusion sessions and has a lower incidence of mild infusion‑related reactions, though both share similar serious hypersensitivity risks.

Injectafer must be stored refrigerated at 2–8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Prior to use, inspect the solution for particulate matter or discoloration and discard if any abnormalities are observed.

Injectafer is administered as an intravenous infusion by a qualified healthcare professional. The infusion rate is controlled according to the prescribed dose, typically over 15–30 minutes for doses up to 1000 mg. Monitoring of vital signs is recommended during and after the infusion.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, acute hypotension, and rare cases of hypophosphatemia that can lead to muscle weakness or bone pain. Prompt recognition and treatment of these events are essential, and patients should be observed closely during infusion.

Injectafer is contraindicated in patients with known hypersensitivity to ferric carboxymaltose or any of its excipients. It should also be avoided in individuals with active severe infections, uncontrolled hypertension, or a history of severe reactions to other intravenous iron products.